S&P 500   5,069.53
DOW   39,069.23
QQQ   436.55
These 2 carnivore dining stocks gaining on the Ozempic craze
Energy Storage Trend Ignites Frenzy Over Vanadium Supply (Ad)
This healthcare stock making a buzz with 160% growth
This infrastructure construction stock: Is it ready to pop?
Critical asset just had biggest fall on record (Ad)
How major US stock indexes fared Monday, 2/26/2024
Is Roku worth a second look after the earnings panic selloff?
Critical asset just had biggest fall on record (Ad)
Is The Trade Desk signaling the rebound of digital advertising?
bluebird bio stock is ripe for a 400% institutional short squeeze
S&P 500   5,069.53
DOW   39,069.23
QQQ   436.55
These 2 carnivore dining stocks gaining on the Ozempic craze
Energy Storage Trend Ignites Frenzy Over Vanadium Supply (Ad)
This healthcare stock making a buzz with 160% growth
This infrastructure construction stock: Is it ready to pop?
Critical asset just had biggest fall on record (Ad)
How major US stock indexes fared Monday, 2/26/2024
Is Roku worth a second look after the earnings panic selloff?
Critical asset just had biggest fall on record (Ad)
Is The Trade Desk signaling the rebound of digital advertising?
bluebird bio stock is ripe for a 400% institutional short squeeze
S&P 500   5,069.53
DOW   39,069.23
QQQ   436.55
These 2 carnivore dining stocks gaining on the Ozempic craze
Energy Storage Trend Ignites Frenzy Over Vanadium Supply (Ad)
This healthcare stock making a buzz with 160% growth
This infrastructure construction stock: Is it ready to pop?
Critical asset just had biggest fall on record (Ad)
How major US stock indexes fared Monday, 2/26/2024
Is Roku worth a second look after the earnings panic selloff?
Critical asset just had biggest fall on record (Ad)
Is The Trade Desk signaling the rebound of digital advertising?
bluebird bio stock is ripe for a 400% institutional short squeeze
S&P 500   5,069.53
DOW   39,069.23
QQQ   436.55
These 2 carnivore dining stocks gaining on the Ozempic craze
Energy Storage Trend Ignites Frenzy Over Vanadium Supply (Ad)
This healthcare stock making a buzz with 160% growth
This infrastructure construction stock: Is it ready to pop?
Critical asset just had biggest fall on record (Ad)
How major US stock indexes fared Monday, 2/26/2024
Is Roku worth a second look after the earnings panic selloff?
Critical asset just had biggest fall on record (Ad)
Is The Trade Desk signaling the rebound of digital advertising?
bluebird bio stock is ripe for a 400% institutional short squeeze
TSE:VPH

Valeo Pharma (VPH) Stock Price, News & Analysis

C$0.18
-0.01 (-5.13%)
(As of 02/26/2024 ET)
Today's Range
C$0.18
C$0.19
50-Day Range
C$0.15
C$0.37
52-Week Range
C$0.13
C$0.58
Volume
7,500 shs
Average Volume
64,486 shs
Market Capitalization
C$18.25 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

VPH stock logo

About Valeo Pharma Stock (TSE:VPH)

Valeo Pharma Inc., a specialty pharmaceutical company, engages in the acquisition, in-licensing brands, and sale of pharmaceuticals and hospital specialty products for unmet medical needs in Canada. Its product portfolio includes Enerzair Breezhaler, a LABA/LAMA/ICS fixed triple dose asthma drug; Atectura Breezhaler, a LABA/ICS dual combination asthma drug; Redesca, to treat and prevent deep vein thrombosis and pulmonary embolism; Onstryv, for the treatment of Idiopathic Parkinson's disease; M-Eslon, extended-release morphine sulphate used for pain management; and Yondelis, a soft tissue sarcoma. It also offers Hesperco, a flavonoid formulation used for immune support; Ethacrynate Sodium; and Amikacin, an antibiotic. In addition, the company provides Ametop Gel 4% for skin anesthesia prior to injection or cannulation; Sabizabulin, an antiviral and anti-inflammatory agent for the treatment of hospitalized moderate-severe COVID-19 patients at high risk for acute respiratory distress syndrome (ARDS) and death; Simbrinza, ophthalmic drops to treat openangle glaucoma or ocular hypertension; Xiidra, a prescription based eye-drop to treat dry eye disease; and Allerject, a portable voice-activated epinephrine injector for emergency treatment of serious allergic reactions. Its primary therapeutic areas include respiratory/allergy, ophthalmology, neurology, oncology, and specialty products. The company was incorporated in 2003 and is based in Kirkland, Canada.

VPH Stock Price History

VPH Stock News Headlines

VALEO PHARMA ANNOUNCES BOARD OF DIRECTORS CHANGES
Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
Valeo Pharma Inc Ordinary Shares VPH
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
Valeo Pharma: Top 10 Undervalued Growth Stocks on TSX (VPH)
See More Headlines
Receive VPH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Valeo Pharma and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
1/29/2024
Today
2/27/2024
Next Earnings (Estimated)
3/20/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Drug Manufacturers - Specialty & Generic
Sub-Industry
N/A
CIK
N/A
Fax
N/A
Employees
110
Year Founded
N/A

Profitability

Net Income
C$-27,810,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
C$53.91 million
Book Value
C($0.41) per share

Miscellaneous

Free Float
N/A
Market Cap
C$18.25 million
Optionable
Not Optionable
Beta
2.61

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report

Key Executives

  • Mr. Steven Saviuk CA (Age 65)
    Vice Chairman, President & CEO
    Comp: $239.7k
  • Mr. Pascal Tougas
    Chief Financial Officer
  • Mr. Frederic Dumais
    Director of Communications & Investor Relations
  • Mr. Guy-Paul Allard
    VP of Legal Affairs & Corporate Secretary
  • Mr. Kyle Steiger
    Senior VP & Chief Commercial Officer
  • Mr. Jean Francois Fournier
    Head of Ophthalmology Business Unit














VPH Stock Analysis - Frequently Asked Questions

Should I buy or sell Valeo Pharma stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Valeo Pharma in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" VPH shares.
View VPH analyst ratings
or view top-rated stocks.

How have VPH shares performed in 2024?

Valeo Pharma's stock was trading at C$0.18 at the start of the year. Since then, VPH stock has increased by 2.8% and is now trading at C$0.19.
View the best growth stocks for 2024 here
.

When is Valeo Pharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 20th 2024.
View our VPH earnings forecast
.

How were Valeo Pharma's earnings last quarter?

Valeo Pharma Inc. (TSE:VPH) announced its quarterly earnings data on Monday, January, 29th. The company reported ($0.10) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.05) by $0.05. The business earned $13.11 million during the quarter, compared to analyst estimates of $16.50 million.

How do I buy shares of Valeo Pharma?

Shares of VPH stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

This page (TSE:VPH) was last updated on 2/27/2024 by MarketBeat.com Staff